StockPreacher.com announces an investment report featuring Labopharm Inc. (Nasdaq:DDSS). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
Labopharm Inc. (DDSS) is an international specialty pharmaceutical company focused on improving existing drugs by incorporating its advanced controlled-release technologies. The Company develops products internally in order to enter into strategic alliances or licensing agreements with national or international pharmaceutical companies that have the necessary resources and distribution networks to market and sell its pharmaceutical products. The Company's wholly owned subsidiaries include Labopharm Europe Ltd., Labopharm (Barbados) Ltd., Labopharm Cyprus Ltd.and Labopharm USA Inc.
Message Board Search for DDSS: http://www.boardcentral.com/boards/DDSS
In the report, the analyst notes:
"Revenue from product sales in all territories for the fourth quarter of fiscal 2009 increased to $4.7 million from $3.3 million for the fourth quarter of fiscal 2008. Revenue from product sales to territories other than the United States was $4.5 million compared with $3.3 million for the fourth quarter of fiscal 2008. The increase was the result of both higher sales volumes and a higher average selling price in the fourth quarter of 2009. Total revenue for the fourth quarter of fiscal 2009 was $6.7 million compared with $4.4 million for the fourth quarter of fiscal 2008.
"DDSS recently announced its wholly owned subsidiary, Labopharm Europe Ltd., has completed a licensing and distribution agreement for once-daily tramadol with Nippon Shinyaku Co. Ltd. of Japan. DDSS will receive an up-front payment upon signature of the agreement and is eligible to receive additional payments related to the achievement of certain regulatory and commercialization milestones. Under the terms of the agreement, Nippon Shinyaku has the exclusive right to market and sell DDSS's once-daily tramadol product in Japan."
To read the entire report visit: http://www.stockpreacher.com/n/DDSS
Tiny magnetic nanorobots show promise for treating brain aneurysms